Betterlife Pharma
- Company typePublic
- Founded2019
- HeadquartersMontreal, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Betterlife Pharma firmographics
Firmographics- Name
- Betterlife Pharma
- Legal name
- BetterLife Pharma Inc.
- Website
- https://abetterlifepharma.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Betterlife Pharma industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industries
- Specialty Care Pharmaceuticals (HLAIAAAB), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where Betterlife Pharma is headquartered
LocationHeadquarters
- HQ city
- Montreal
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Betterlife Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Development and Commercialization: Pre-revenue biotech company focused on developing and commercializing patient-friendly compounds to treat neuro-psychiatric and neurological disorders. Revenue expected upon regulatory approval and commercialization of BETR-001 and other pipeline compounds.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Betterlife Pharma product offering
Product offeringCore offering
BetterLife Pharma is a clinical-stage biotechnology company developing BETR-001 (2-Bromo-LSD), a non-hallucinogenic second-generation LSD derivative for treating neuro-psychiatric and neurological disorders including treatment-resistant depression, PTSD, anxiety, and chronic cluster headaches. The company is advancing BETR-001 through IND-enabling studies toward a Q1 2027 FDA IND filing and Phase 1 clinical trials. Additional pipeline assets include BETR-002 for neuro-psychiatric disorders and AP-003 (recombinant interferon alpha-2b) for COVID-19.
Product overview
BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing compounds to treat neuro-psychiatric and neurological disorders. The company's lead pipeline consists of BETR-001 (2-Bromo-LSD), a non-hallucinogenic LSD derivative being developed for treatment-resistant depression, PTSD, and cluster headaches; BETR-002 for neuro-psychiatric disorders; and AP-003 (rhIFNα2b), an interferon-based therapy that completed Phase 1/2 COVID-19 trials. The company also worked on TD-0148A (which is the same compound as BETR-001) and TD-010 for anxiolytic-use disorder. BetterLife operates as a pure biotech with no software products or platform offerings.
Differentiator
Problem solved
Functional benefit
Products and services
- BETR-001 (2-Bromo-LSD) Lead product candidate — a second-generation non-hallucinogenic LSD derivative molecule being developed for treating neuro-psychiatric and neurological disorders including treatment-resistant depression, PTSD, anxiety, and chronic cluster headaches. Mimics projected therapeutic properties of LSD without hallucinogenic side effects and is patient self-administered.
- BETR-002 Biotech compound being developed for neuro-psychiatric disorders alongside BETR-001 as part of BetterLife Pharma's psychedelic derivative pipeline.
- AP-003 (rhIFNα2b) Recombinant interferon alpha-2b product that completed Phase 1 and initiated Phase 2 clinical trials for COVID-19 treatment in Chile, conducted with Pontificia Universidad Católica de Chile.
Quantifiable outcome
- Demonstrated anti-depressant activity in preclinical models of depression
- +3 more outcomes
Companies that use Betterlife Pharma
Customer profileSegments2 records
Ideal customer profiles2 records
Betterlife Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Betterlife Pharma partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, minor and supporting.
- Syner-G BioPharma GroupcoreBetterLife Pharma engaged Syner-G BioPharma Group to oversee GMP manufacturing of BETR-001. Syner-G provides CMC and regulatory expertise to support the company's path to first-in-human clinical studies and IND filing.
- GTM StudiosminorBetterLife engaged Vancouver-based GTM Studios for two months of marketing material production at $4,000 per month.
- YAFO CapitalcoreBetterLife Pharma engaged Shanghai-based YAFO Capital to seek strategic partnerships for developing BETR-001 in Greater China. YAFO will leverage its network to facilitate development and partnerships in Asia.
- Daniel CarcillosupportingFormer NHL player Daniel Carcillo appointed as Corporate Advisor, bringing patient advocacy perspective for traumatic brain injury and mental health.
- Medical College WisconsinsupportingBetterLife entered research agreement with Medical College Wisconsin for TD-0148A neurological receptor studies.
- Dr. Thomas LaughrensupportingFormer FDA Psychiatry Division Director Dr. Thomas Laughren joined BetterLife as Regulatory Advisor, providing guidance on FDA regulatory pathway for BETR-001.
- University of California San Diego (UCSD)supportingBetterLife entered research agreement with UCSD for TD-0148A behavioural pharmacology studies, working with researchers including Adam Halberstadt.
- Carleton UniversitysupportingBetterLife entered research agreement with Carleton University for TD-0148A depression studies. The collaboration has received Mitacs Accelerate funding for chronic anxiety and depression research.
- Eurofins CDMO (Alphora)supportingBetterLife engaged Eurofins CDMO for next generation psychedelic TD-0148A manufacturing.
- Eurofins DiscoverysupportingBetterLife engaged Eurofins Discovery for next generation psychedelics 2-bromo-LSD FDA IND-enabling pharmacology studies.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Betterlife Pharma competitors and assessment
Company assessmentDirect peers
- atai Life Sciences: atai Life Sciences is a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic therapies for mental health. It operates a portfolio approach similar in spirit to BetterLife's multi-indication CNS strategy.
- GH Research PLC: GH Research is a clinical-stage biopharmaceutical company developing mebufotenin and other tryptamine-based therapies for treatment-resistant depression. It targets the same patient population as BETR-001 with a similarly differentiated psychedelic mechanism.
- Bright Minds Biosciences: Bright Minds Biosciences is a clinical-stage biotech developing novel serotonergic compounds (including 5-HT2C and 5-HT2A agonists) for epilepsy and CNS disorders. It is a direct psychedelic-adjacent CNS peer with similar mechanism-based differentiation.
- Cybin Inc. Cybin is a clinical-stage psychedelic CNS biotech developing psilocybin analogs and deuterated tryptamines for depression and other neuropsychiatric indications. It is the most directly comparable psychedelic CNS peer, and former Cybin CEO Doug Drysdale now chairs BetterLife.
- Mind Medicine (MindMed) Inc. MindMed is a clinical-stage psychedelic biotech developing LSD-based therapies (including an LSD neutralizer) and other neuropsychiatric candidates. It directly competes with BetterLife in LSD-derivative neuropsychiatric development and shares the same psychedelic CNS therapeutic thesis.
- Compass Pathways plc: Compass Pathways is a mental health care company developing psilocybin therapy for treatment-resistant depression. It is a direct competitor in psychedelic-based depression treatment and the most advanced clinical peer in this indication.
Emerging players
- Lobe Sciences: Lobe Sciences is an emerging biotech developing psychedelic-inspired therapeutics for neurological and mental health conditions. It is a smaller-scale comparator pursuing adjacent neuropsychiatric indications to BetterLife.
- Field Trip Health & Therapeutics: Field Trip operates psychedelic-assisted therapy clinics and is developing next-generation psychedelic compounds. It overlaps with BetterLife's neuropsychiatric focus through both drug development and the patient funnel for psychedelic mental health treatment.
Broad incumbents
- Eli Lilly (Lilly Neuroscience): Lilly is a global pharmaceutical incumbent with a major CNS and depression franchise (Cymbalta, Zepbound adjacencies). It represents the strategic-partner or acquirer profile that BetterLife's BETR-001 could attract if clinical data de-risks the asset.
- Psilocybin/SSRI-class developers (e.g., Sage Therapeutics): Sage Therapeutics develops CNS-targeted therapies for depression and neurological disorders (e.g., Zurzuvae for postpartum depression). It is a broader incumbent CNS player whose indications overlap with BETR-001's target markets and provides a benchmark for CNS drug commercialisation economics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks1 record
Key highlights7 records
Customer concentration
Betterlife Pharma social profiles
Digital presenceBetterlife Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Betterlife Pharma leadership team
Management profileNumber of profiles
Profiles8 records
Betterlife Pharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
Betterlife Pharma funding detail
Funding detailFunding overview
Funding rounds13 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Betterlife Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Betterlife Pharma
What does Betterlife Pharma do?
BetterLife Pharma is a clinical-stage biotechnology company developing BETR-001 (2-Bromo-LSD), a non-hallucinogenic second-generation LSD derivative for treating neuro-psychiatric and neurological disorders including treatment-resistant depression, PTSD, anxiety, and chronic cluster headaches. The company is advancing BETR-001 through IND-enabling studies toward a Q1 2027 FDA IND filing and Phase 1 clinical trials. Additional pipeline assets include BETR-002 for neuro-psychiatric disorders and AP-003 (recombinant interferon alpha-2b) for COVID-19.
Is Betterlife Pharma a public or private company?
Betterlife Pharma is a public company. It is classified as public and is currently operating.
When was Betterlife Pharma founded?
Betterlife Pharma was founded in 2019. It employs 11 to 50 people.
Where is Betterlife Pharma based?
Betterlife Pharma is headquartered in Montreal, Canada, in the North America region.
How does Betterlife Pharma make money?
One revenue line is on record: pharmaceutical Development and Commercialization.
Who are Betterlife Pharma's main competitors?
Direct peers on record are atai Life Sciences, GH Research PLC, Bright Minds Biosciences, Cybin Inc., Mind Medicine (MindMed) Inc. and Compass Pathways plc. Emerging players are Lobe Sciences and Field Trip Health & Therapeutics. Broad incumbents are Eli Lilly (Lilly Neuroscience) and Psilocybin/SSRI-class developers (e.g., Sage Therapeutics).
Does Betterlife Pharma have an API?
No public API is recorded for Betterlife Pharma.
What industry is Betterlife Pharma in?
Betterlife Pharma's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.